- Home
- NXTC vs MRKR Comparison
NXTC vs MRKR Comparison
Compare NXTC & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- MRKR
- Stock Information
- Founded
- NXTC 2015
- MRKR N/A
- Country
- NXTC United States
- MRKR United States
- Employees
- NXTC N/A
- MRKR N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- MRKR Health Care
- Exchange
- NXTC Nasdaq
- MRKR Nasdaq
- Market Cap
- NXTC 12.8M
- MRKR 13.7M
- IPO Year
- NXTC 2019
- MRKR N/A
- Fundamental
- Price
- NXTC $4.85
- MRKR $0.90
- Analyst Decision
- NXTC Strong Buy
- MRKR Strong Buy
- Analyst Count
- NXTC 2
- MRKR 3
- Target Price
- NXTC $25.50
- MRKR $13.17
- AVG Volume (30 Days)
- NXTC 18.5K
- MRKR 2.6M
- Earning Date
- NXTC 11-06-2025
- MRKR 08-14-2025
- Dividend Yield
- NXTC N/A
- MRKR N/A
- EPS Growth
- NXTC N/A
- MRKR N/A
- EPS
- NXTC N/A
- MRKR N/A
- Revenue
- NXTC N/A
- MRKR $5,388,071.00
- Revenue This Year
- NXTC N/A
- MRKR N/A
- Revenue Next Year
- NXTC N/A
- MRKR $15.82
- P/E Ratio
- NXTC N/A
- MRKR N/A
- Revenue Growth
- NXTC N/A
- MRKR 44.55
- 52 Week Low
- NXTC $2.69
- MRKR $0.81
- 52 Week High
- NXTC $19.20
- MRKR $5.95
- Technical
- Relative Strength Index (RSI)
- NXTC 41.16
- MRKR 32.98
- Support Level
- NXTC $4.83
- MRKR $0.81
- Resistance Level
- NXTC $5.15
- MRKR $0.98
- Average True Range (ATR)
- NXTC 0.23
- MRKR 0.10
- MACD
- NXTC -0.02
- MRKR -0.02
- Stochastic Oscillator
- NXTC 7.14
- MRKR 14.71
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.